Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Neurturin** is a protein growth factor belonging to the glial cell line-derived neurotrophic factor (GDNF) family, classified as a neurotrophic factor and part of the TGF-beta superfamily. It plays a critical role in supporting the survival, development, and maintenance of neurons, particularly midbrain dopaminergic neurons relevant to diseases such as Parkinson's. Neurturin mediates its effects primarily through the GDNF family receptor alpha-2 (GFRα2) and the receptor tyrosine kinase RET, leading to cellular survival signaling and upregulation of tyrosine hydroxylase in the nigrostriatal system. As a protein itself, neurturin has served as a therapeutic transgene in gene therapy clinical trials for neuroprotection and disease-modification in Parkinson's disease, most notably delivered via vectors such as AAV2-neurturin (CERE-120)[1][5][6][3][4][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on neurturin.